Affiliation:
1. Institute for Nuclear Research and Nuclear Energy at the Bulgarian Academy of Sciences, Sofia, Bulgaria
Abstract
Over the past decade, antisense technology has successfully established itself as an entirely innovative platform for research and creation of new therapies. Significant advances in the design of antisense oligonucleotides, as well as a deeper understanding of their mechanisms of action, have led to their successful clinical application in many RNA-targeted therapies. In addition, their potential for in vivo imaging by radiolabeling has been identified. Here are discussed the prospects for the use of antisense oligonucleotides in nuclear medicine and highlighted some of the advantages and disadvantages of labelling them with radionuclides.
Publisher
National Society of Ecological Engineering and Environment Protection